- Home
- SGA vs SLGL Comparison
SGA vs SLGL Comparison
Compare SGA & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGA
- SLGL
- Stock Information
- Founded
- SGA 1986
- SLGL 1997
- Country
- SGA United States
- SLGL Israel
- Employees
- SGA N/A
- SLGL N/A
- Industry
- SGA Broadcasting
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- SGA Consumer Discretionary
- SLGL Health Care
- Exchange
- SGA Nasdaq
- SLGL Nasdaq
- Market Cap
- SGA 84.1M
- SLGL 69.1M
- IPO Year
- SGA 1992
- SLGL 2018
- Fundamental
- Price
- SGA $12.03
- SLGL $23.98
- Analyst Decision
- SGA
- SLGL
- Analyst Count
- SGA 0
- SLGL 0
- Target Price
- SGA N/A
- SLGL N/A
- AVG Volume (30 Days)
- SGA 10.5K
- SLGL 33.1K
- Earning Date
- SGA 11-06-2025
- SLGL 11-14-2025
- Dividend Yield
- SGA 8.26%
- SLGL N/A
- EPS Growth
- SGA N/A
- SLGL N/A
- EPS
- SGA 0.33
- SLGL N/A
- Revenue
- SGA $110,350,000.00
- SLGL $23,931,000.00
- Revenue This Year
- SGA N/A
- SLGL N/A
- Revenue Next Year
- SGA $5.37
- SLGL $31.17
- P/E Ratio
- SGA $36.97
- SLGL N/A
- Revenue Growth
- SGA N/A
- SLGL 264.86
- 52 Week Low
- SGA $10.75
- SLGL $4.01
- 52 Week High
- SGA $15.10
- SLGL $30.00
- Technical
- Relative Strength Index (RSI)
- SGA 40.29
- SLGL 58.56
- Support Level
- SGA $11.80
- SLGL $23.13
- Resistance Level
- SGA $12.17
- SLGL $24.85
- Average True Range (ATR)
- SGA 0.28
- SLGL 2.36
- MACD
- SGA -0.02
- SLGL -0.43
- Stochastic Oscillator
- SGA 16.91
- SLGL 39.19
About SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.